Literature DB >> 24091354

Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.

Frederico Leal, Ligia T Macedo, José Barreto C Carvalheira.   

Abstract

INTRODUCTION: Thrombotic microangiopathy (TMA) has been reported as a complication of chemotherapy. Many antineoplastic agents have been linked to TMA, gemcitabine being one of the most frequently cited as related to this syndrome.
METHODS: A retrospective search for chemotherapy-induced TMA cases among gemcitabine users in a single oncology centre from January 2009 to September 2012 was performed.
RESULTS: Three cases of gemcitabine-induced TMA were reported, from a total of 264 patients (incidence: 1·13%) who received the drug. From the three cases reported, two (66%) patients died as a consequence of the syndrome. DISCUSSION: These findings are compatible with previous analyses, which report an incidence of gemcitabine-associated TMA ranging from 0·008 to 2·2% and mortality rates from 15 to 90%. Unlike previously reported, however, cumulative dose was not predictive of risk.
CONCLUSION: Gemcitabine-induced TMA is an underdiagnosed condition characterized by high mortality rates. Attention should be called for a higher level of awareness to provide early diagnosis and proper treatment.

Entities:  

Keywords:  Chemotherapy,; Drug toxicity,; Gemcitabine,; Thrombotic microangiopathies; Thrombotic thrombocytopenic purpura,

Mesh:

Substances:

Year:  2013        PMID: 24091354     DOI: 10.1179/1973947813Y.0000000122

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

2.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

3.  ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.

Authors:  Peter G Bittar; Myles S Nickolich; Oluwatoyosi A Onwuemene
Journal:  J Clin Apher       Date:  2017-09-23       Impact factor: 2.821

4.  A rare case report of gemcitabine-induced thrombotic microangiopathies.

Authors:  Mohammed Ali Madkhali
Journal:  SAGE Open Med Case Rep       Date:  2021-05-24

5.  Eculizumab in chemotherapy-induced thrombotic microangiopathy.

Authors:  Lena Schulte-Kemna; Barbara Reister; Lucas Bettac; Ulla Ludwig; Daniel Fürst; Joannis Mytilineos; Carsten Bergmann; Rene van Erp; Bernd Schröppel
Journal:  Clin Nephrol Case Stud       Date:  2020-04-17

6.  An Update in Drug-Induced Thrombotic Microangiopathy.

Authors:  Thomas Chatzikonstantinou; Maria Gavriilaki; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  Front Med (Lausanne)       Date:  2020-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.